Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 5 of 116

  1. BT8009-230

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  2. BT8009-230

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  3. BX44273

    Hoffmann-La Roche

    This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally

    phase 3 small molecule active

    1 trial

  4. Bacillus Calmette Guerin and interferon alpha

    Hospital Authority, Hong Kong

    Carcinoma of Urinary Bladder, Superficial

    phase 3 small molecule completed

    1 trial

  5. Bavencio 20 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Solid Tumors

    phase 3 small molecule active

    1 trial

  6. Bel-sar

    Aura Biosciences

    Choroidal Melanoma

    phase 3 small molecule active

    1 trial

  7. Bempegaldesleukin

    Nektar Therapeutics UK Limited

    Melanoma

    phase 3 mab terminated

    1 trial

  8. Bempegaldesleukin

    Nektar Therapeutics UK Limited

    Metastatic Head and Neck Cancer

    phase 3 small molecule terminated

    1 trial

  9. Bendamustine

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    1 trial

  10. Bendamustine HCl

    Teva Pharma GmbH

    Non-Hodgkin's Lymphoma

    phase 3 small molecule completed

    1 trial

  11. Bendamustine hydrochloride

    Teva Pharma GmbH

    Non-Hodgkin Lymphoma

    phase 3 small molecule completed

    1 trial

  12. Bevacizumab

    Samsung Bioepis NL B.V.

    Lung Cancer

    phase 3 small molecule completed

    1 trial

  13. Bevacizumab

    Pfizer

    Renal Cell Carcinoma

    phase 3 small molecule completed

    1 trial

  14. Bevacizumab

    Hoffmann-La Roche

    B-cell Lymphoma

    phase 3 small molecule terminated

    1 trial

  15. Bevacizumab

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  16. Bevacizumab-Pfizer

    Pfizer

    Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  17. Bosutinib

    Pfizer

    Chronic Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  18. Brentuximab Vedotin

    Takeda

    Primary Cutaneous Anaplastic Large Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  19. Brentuximab Vedotin for Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Classical Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  20. Brentuximab vedotin

    Pfizer

    Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  21. Brentuximab vedotin

    Takeda

    Diffuse Large B-cell-lymphoma

    phase 3 small molecule active

    1 trial

  22. Brigimadlin

    Boehringer Ingelheim

    Liposarcoma, Dedifferentiated

    phase 3 small molecule completed

    1 trial

  23. Bupivacaine

    Pacira Ireland Limited

    Malignant Neoplasms of Female Genital Organs

    phase 3 small molecule terminated

    1 trial

  24. Busulfan (BU)

    The First People's Hospital of Lianyungang

    Primary Central Nervous System Lymphoma

    phase 3 small molecule active

    1 trial

  25. C16-40

    The George Institute

    Unresectable locally advanced and/or metastatic soft-tissue sarcoma

    phase 3 small molecule active

    1 trial

  26. C2321003

    Pfizer Australia Pty Ltd

    METASTATIC CASTRATION RESISTANT PROSTATE CANCER

    phase 3 small molecule active

    1 trial

  27. C2321008

    Pfizer Australia Pty Ltd

    METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

    phase 3 small molecule active

    1 trial

  28. C2321014

    Pfizer Australia Pty Ltd

    METASTATIC CASTRATION RESISTANT PROSTATE CANCER

    phase 3 small molecule active

    1 trial

  29. C25003

    Takeda

    Advanced Classical Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  30. C3441021

    Pfizer Australia Pty Ltd

    Metastatic Castration-resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  31. C3441052

    Pfizer Australia Pty Ltd

    Metastatic Castration-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  32. C3651021

    Pfizer Australia Pty Ltd

    Cancer cachexia

    phase 3 small molecule active

    1 trial

  33. C4221015

    Pfizer Australia Pty Ltd

    Colorectal cancer (BRAF V600E-mutant mCRC)

    phase 3 small molecule active

    1 trial

  34. C4221016

    Pfizer Australia Pty Ltd

    Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma

    phase 3 small molecule active

    1 trial

  35. C4391022

    Pfizer Australia Pty Ltd

    Hormone receptor-positive, her2-negative advanced/metastatic breast cancer

    phase 3 small molecule active

    1 trial

  36. C4391024

    Pfizer Australia Pty Ltd

    Advanced/Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  37. C4551002

    Pfizer Australia Pty Ltd

    Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  38. C5751003

    Pfizer Australia Pty Ltd

    non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  39. C6461001

    Pfizer Australia Pty Ltd

    LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

    phase 3 small molecule active

    1 trial

  40. C6461003

    Pfizer Australia Pty Ltd

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  41. C6461004

    Pfizer Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  42. CA017-078

    Bristol-Myers Squibb Australia Pty Ltd

    Bladder Cancer Muscle-Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  43. CA071-1000

    Celgene Europe Limited

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  44. CA073-1003

    Celgene Europe Limited

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  45. CA073-1020

    Celgene Europe Limited

    High-risk Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  46. CA127-1030

    Bristol-Myers Squibb Australia Pty Ltd

    Non small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  47. CA209-577

    Bristol-Myers Squibb Australia Pty Ltd

    Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer

    phase 3 small molecule active

    1 trial

  48. CA209-67T

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.